Figure 1.
(A) Selection of high affinity neurokinin NK2 and NK3 antagonists with peptidic, pseudopeptidic, and non-peptidic scaffolds. (B) Design of opioid agonist–NK2/NK3 antagonist hybrids and molecular structure of composing pharmacophores.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.